These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 238480)

  • 41. [The new beta blocker Betapressin. Long-term experience in hypertensive patients in ambulatory care].
    Dameris W
    ZFA (Stuttgart); 1981 Mar; 57(8):628-32. PubMed ID: 6111871
    [No Abstract]   [Full Text] [Related]  

  • 42. Preliminary report on the haemodynamic response of hypertensive patients treated with a beta blocker (ICI 66082).
    Amery A; Billiet L; Joossens JV; Meekers J; Reybrouck T; Van Mieghem W
    Acta Clin Belg; 1973; 28(5):358-63. PubMed ID: 4149691
    [No Abstract]   [Full Text] [Related]  

  • 43. [Evaluation of hypotensive effect of nadolol].
    Cybulska I; Brym E; Czerniewska E; Wołyńczyk-Niegowska J
    Pol Arch Med Wewn; 1980 Dec; 64(6):475-80. PubMed ID: 6111065
    [No Abstract]   [Full Text] [Related]  

  • 44. Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on blood pressure in hypertensive patients known to respond to beta 1-adrenoceptor antagonists.
    Robb OJ; Webster J; Petrie JC; Harry JD; Young J
    Br J Clin Pharmacol; 1988 Apr; 25(4):433-8. PubMed ID: 2898256
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the antihypertensive effect of a beta-blocker with the aid of daily blood pressure profiles.
    Abetel G; Karly M; Genoud G
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S77-9. PubMed ID: 2439827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function.
    Dupont AG; Vanderniepen P; Bossuyt AM; Jonckheer MH; Six RO
    Br J Clin Pharmacol; 1985 Aug; 20(2):93-9. PubMed ID: 2864051
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma renin concentration and the hypotensive effect of bendrofluazide and of atenolol.
    Fagard R; Amery A; Deplaen JF; Lijnen P; Missotten A
    Clin Sci Mol Med Suppl; 1976 Dec; 3():215s-217s. PubMed ID: 799551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients.
    Dahlöf B; Danielson M; Andersson O; Thulin T; Ohman P; Mörlin C; Boberg J; Karlberg BE; Jern S; Hansson L
    Br J Clin Pharmacol; 1984 Dec; 18(6):831-6. PubMed ID: 6152175
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Timolol maleate (Blocadren) in the treatment of essential hypertension.
    O'Brien KP
    N Z Med J; 1975 Nov; 82(551):293-6. PubMed ID: 1695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Antihypertensive effect of betaxolol, a cardioselective beta-adrenoceptor antagonist, in renal hypertensive dogs].
    Bessho H; Suzuki J; Kitada Y; Narimatsu A; Tobe A
    Nihon Yakurigaku Zasshi; 1990 Jun; 95(6):355-60. PubMed ID: 1974239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Hemodynamic correlates of selective beta 1 adrenergic receptor blockade by cordanum during hemiton monotherapy in children with primary arterial hypertension].
    Kapliev VA
    Pediatriia; 1988; (9):112. PubMed ID: 2904673
    [No Abstract]   [Full Text] [Related]  

  • 52. Hyperdynamic circulation and hypertension.
    Frohlich ED
    Postgrad Med; 1972 Sep; 52(3):68-73. PubMed ID: 4403455
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy of bucindolol in systemic hypertension.
    Kimura S; DeQuattro V; Edmiston WA; Loo R; Thien S; Rigonan K; Deitchman D; Foti A
    Am J Cardiol; 1987 Nov; 60(13):1083-6. PubMed ID: 2890292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Hypertension treatment with a new retard form of a beta-blocker (result of a practice study)].
    Degenring FH; Walch HG; Ziegler E
    ZFA (Stuttgart); 1981 Oct; 57(30):2093-5. PubMed ID: 6118981
    [No Abstract]   [Full Text] [Related]  

  • 55. Haemodynamic effects of indenolol at rest and after a submaximal workload in essential hypertension.
    Aiello C; Groothold G; Gualtieri S; Irace L; Marini IL; Perna B; Romano A
    Eur J Clin Pharmacol; 1985; 28(5):501-5. PubMed ID: 3899670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of nadolol in treatment of hypertension.
    Volicer L; Liang CS; Gavras H; Tifft CP; Kershaw GR; Gavras I; Griffith DL; Vukovitch R; Brunner HR
    J Clin Pharmacol; 1979; 19(2-3):137-47. PubMed ID: 33998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of the antihypertensive effect of atenolol with 24 h ambulatory monitoring of blood pressure.
    Floras JS; Fox P; Hassan MO; Jones JV; Sleight P; Turner KL
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():387s-389s. PubMed ID: 540457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ask the doctor. My doctor recently put me on Tenormin because my blood pressure was getting high. Now, when I run or row, I can't get my heart rate much above 115 beats per minute even though my peak heart rate should be 136. Is the beta blocker keeping me from getting the full benefit of exercise?
    Lee R
    Harv Heart Lett; 2011 Dec; 22(4):5. PubMed ID: 22319828
    [No Abstract]   [Full Text] [Related]  

  • 59. Overview of clinical safety and efficacy of tertatolol.
    Vivet P
    Cardiology; 1993; 83 Suppl 1():41-50. PubMed ID: 7903214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Therapeutic effect of the cardioselective beta-blocking agent tenormin and its action on the indices of systemic, intracardiac and regional hemodynamics in patients with hypertension].
    Erina EV; Charyev KhE; Oshchepkova EV
    Kardiologiia; 1983 Apr; 23(4):53-9. PubMed ID: 6865186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.